-
EP4448526
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4448526
| EP4448526 - PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 27.06.2025 Database last updated on 21.03.2026 | |
| Former | Request for examination was made Status updated on 19.09.2024 | ||
| Former | The international publication has been made Status updated on 24.06.2023 | ||
| Former | unknown Status updated on 10.02.2023 | Most recent event Tooltip | 20.03.2026 | New entry: Reply to examination report | 20.03.2026 | New entry: Fee payment for request for further processing | Applicant(s) | For all designated states GENZYME CORPORATION 450 Water Street Cambridge, Massachusetts 02141 / US | For all designated states Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, CA 94063 / US | [2024/43] | Inventor(s) | 01 /
BEGIS, Guillaume 75017 Paris / FR | 02 /
BIANCIOTTO, Marc 75017 Paris / FR | 03 /
DEVILLERS, Ingrid 75017 Paris / FR | 04 /
FORICHER, Yann 75017 Paris / FR | 05 /
GENEVOIS-BORELLA, Arielle 75017 Paris / FR | 06 /
GILL, Adrian L. Redwood City, California 94063 / US | 07 /
KARLSSON, Andreas 75017 Paris / FR | 08 /
KOLTUN, Elena S. Redwood City, California 94063 / US | [2024/43] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2024/43] | Application number, filing date | 22851447.7 | 16.12.2022 | [2024/43] | WO2022US81729 | Priority number, date | US202163291012P | 17.12.2021 Original published format: US 202163291012 P | US202263431260P | 08.12.2022 Original published format: US 202263431260 P | [2024/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023114954 | Date: | 22.06.2023 | Language: | EN | [2023/25] | Type: | A1 Application with search report | No.: | EP4448526 | Date: | 23.10.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.06.2023 takes the place of the publication of the European patent application. | [2024/43] | Search report(s) | International search report - published on: | EP | 22.06.2023 | Classification | IPC: | C07D471/10, C07D487/04, C07D491/107, C07D491/20, C07D493/10, C07D513/10, A61P35/00, A61K31/431, A61K31/438 | [2024/43] | CPC: |
C07D491/107 (EP);
C07D487/04 (EP,US);
A61K31/4985 (US);
A61K31/501 (US);
A61K31/506 (US);
A61K31/5377 (US);
A61P35/00 (EP);
C07D471/10 (EP);
C07D491/20 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/43] | Title | German: | PYRAZOLOPYRAZINVERBINDUNGEN ALS SHP2-INHIBITOREN | [2024/43] | English: | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | [2024/43] | French: | COMPOSÉS PYRAZOLOPYRAZINE UTILISÉS COMME INHIBITEURS DE LA SHP2 | [2024/43] | Entry into regional phase | 12.07.2024 | National basic fee paid | 12.07.2024 | Designation fee(s) paid | 12.07.2024 | Examination fee paid | Examination procedure | 12.07.2024 | Amendment by applicant (claims and/or description) | 12.07.2024 | Examination requested [2024/43] | 12.07.2024 | Date on which the examining division has become responsible | 30.06.2025 | Despatch of a communication from the examining division (Time limit: M06) | 21.01.2026 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 18.03.2026 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 18.03.2026 | Request for further processing filed | 18.03.2026 | Full payment received (date of receipt of payment) Request granted | 26.03.2026 | Decision despatched | Fees paid | Renewal fee | 27.12.2024 | Renewal fee patent year 03 | 29.12.2025 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I] WO2020063760 (JACOBIO PHARMACEUTICALS CO LTD et al.) | [IP] WO2022166844 (HUTCHMED LTD et al.) | by applicant | US6352694 | US6534055 | US6905680 | US6692964 | US5858358 | US6887466 | US6905681 | US7144575 | US7067318 | US7172869 | US7232566 | US7175843 | US7572631 | US5883223 | US6905874 | US6797514 | US6867041 | US6258812 | US6630500 | US6515004 | US6713485 | US5521184 | US5770599 | US5747498 | US5990141 | US6235764 | US8623885 | WO0137820 | WO0132651 | WO02068406 | WO02066470 | WO02055501 | WO2004005279 | WO2004007481 | WO2004007458 | WO2004009784 | WO02059110 | WO9945009 | WO0059509 | WO9961422 | WO0012089 | WO0002871 | WO2005016894 | WO2021173524 | WO2021130731 | WO2021127429 | WO2021092115 | WO2021105960 | WO2021074227 | WO2020180768 | WO2020180770 | WO2020173935 | WO2020146470 | WO2019201848 | WO2019122129 | WO2018172250 | WO2018115380 | WO2021091982 | WO2021091967 | WO2021091956 | WO2020132597 | WO2022133038 | WO2022133345 | WO2022132200 | WO2022119748 | WO2022109485 | WO2022109487 | WO2022066805 | WO2021239058 | WO2021236920 | WO2021231526 | WO2021228161 | WO2021222333 | WO2021219091 | WO2021219090 | WO2021219072 | WO2021218939 | WO2021217019 | WO2021216770 | WO2021215545 | WO2021215544 | WO2021211864 | WO2021197499 | WO2021190467 | WO2021185233 | WO2021180181 | WO2021175199 | WO2021173923 | WO2021169990 | WO2021169963 | WO2021168193 | WO2021158071 | WO2021155716 | WO2021152149 | WO2021150613 | WO2021147967 | WO2021147965 | WO2021143693 | WO2021142252 | WO2021141628 | WO2021139748 | WO2021139678 | WO2021129824 | WO2021129820 | WO2021127404 | WO2021126816 | WO2021126799 | WO2021124222 | WO2021121371 | WO2021121367 | WO2021121330 | WO2020050890 | WO2020047192 | WO2020035031 | WO2020028706 | WO2019241157 | WO2019232419 | WO2019217691 | WO2019217307 | WO2019215203 | WO2019213526 | WO2019213516 | WO2019155399 | WO2019150305 | WO2019110751 | WO2019099524 | WO2019051291 | WO2018218070 | WO2018217651 | WO2018218071 | WO2018218069 | WO2018206539 | WO2018143315 | WO2018140600 | WO2018140599 | WO2018140598 | WO2018140514 | WO2018140513 | WO2018140512 | WO2018119183 | WO2018112420 | WO2018068017 | WO2018064510 | WO2017201161 | WO2017172979 | WO2017100546 | WO2017087528 | WO2017058807 | WO2017058805 | WO2017058728 | WO2017058902 | WO2017058792 | WO2017058768 | WO2017058915 | WO2017015562 | WO2016168540 | WO2016164675 | WO2016049568 | WO2016049524 | WO2015054572 | WO2014152588 | WO2014143659 | WO2013155223 | CH8765549 | CH2676651 | EP0520722 | EP0566226 | WO9633980 | WO9630347 | EP0787772 | WO9730034 | WO9730044 | WO9738994 | WO9749688 | EP0837063 | WO9802434 | WO9738983 | WO9519774 | WO9519970 | WO9713771 | WO9802437 | WO9802438 | WO9732881 | DE19629652 | WO9833798 | WO9732880 | EP0682027 | WO9702266 | WO9727199 | WO9807726 | WO9734895 | WO9631510 | WO9814449 | WO9814450 | WO9814451 | WO9509847 | WO9719065 | WO9817662 | US5789427 | US5650415 | US5656643 | WO9935146 | WO9935132 | WO9907701 | WO9220642 | WO2006044453 | WO2009036082 | WO2009055730 | WO2006122806 | WO2008070740 | WO2005011700 | US6656963 | WO9409010 | WO9802441 | WO0114387 | WO2005005434 | US5258389 | US5118677 | US5118678 | US5100883 | US5151413 | US5120842 | US5256790 | WO9419010 | WO9205179 | WO9311130 | WO9402136 | WO9402485 | WO9514023 | WO9516691 | WO9641807 | WO2018204416 | WO2005016252 | WO2019212990 | WO2019212991 | WO2006121168 | US6111090 | US8586023 | WO2010003118 | WO2011090754 | US7025962 | EP1947183 | US7812135 | US8388967 | US8591886 | US7618632 | EP1866339 | WO2011028683 | WO2013039954 | WO2005007190 | WO2007133822 | WO2005055808 | WO9940196 | WO0103720 | WO9920758 | WO2006083289 | WO2005115451 | WO2011051726 | WO9633172 | WO9627583 | WO9807697 | WO9803516 | WO9834918 | WO9834915 | WO9833768 | WO9830566 | WO9005719 | WO9952910 | WO9952889 | WO9929667 | WO9907675 | EP0606046 | EP0780386 | EP1786785 | EP1181017 | EP0818442 | EP1004578 | US2009012085 | US5863949 | US5861510 | US2003162712 | US6413932 | US6727225 | US2002042368 | US5981245 | US5728813 | US5969110 | US6596852 | US6232447 | US6057124 | US5892112 | US5792783 | EP0970070 | JPH02233610 | EP0407122 | CHAN, G ET AL., CANCER METASTASIS REV, vol. 27, 2008, pages 179 - 192 | ZHANG, J. ET AL., J. CELL. MOL. MED., vol. 19, 2015, pages 2075 - 2083 | ROCCOGRANDI L. ET AL., J. NEURO-ONCOL., vol. 135, 2017, pages 487 - 496 | MITRA R ET AL., CHEMMEDCHEM, vol. 16, 2021, pages 777 - 787 | FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: 10.1016/0165-6147(84)90534-0 DOI: http://dx.doi.org/10.1016/0165-6147(84)90534-0 | BLACK ET AL., NEUROLOGY, vol. 65, 2005, pages S3 - S6 | SALTZ ET AL., PROC. AM. SOC. CLIN. ONCOL., vol. 18, 1999, pages 233a | DOUILLARD ET AL., LANCET, vol. 355, no. 9209, 2000, pages 1041 - 1047 | AGNEW, CHEM. INTL. ED ENGL., vol. 33, 1994, pages 183 - 186 | CANCERS (BASEL, vol. 7, no. 3, September 2015 (2015-09-01), pages 1758 - 1784 | ROCHE, PLOS ONE, vol. 9, no. 11, 25 November 2014 (2014-11-25) | CLIN CANCER RES., vol. 17, no. 5, 1 March 2011 (2011-03-01), pages 989 - 1000 | MODJTAHEDI ET AL., BR. J. CANCER, vol. 67, 1993, pages 247 - 253 | TERAMOTO ET AL., CANCER, vol. 77, 1996, pages 639 - 645 | GOLDSTEIN ET AL., CLIN. CANCER RES., vol. 1, 1995, pages 1311 - 1318 | HUANG ET AL., CANCER RES., vol. 59, 1999, pages 1236 - 1243 | YAN ET AL.: "Pharmacogenetics and Pharmacogenomics In Oncology Therapeutic Antibody Development", BIOTECHNIQUES, vol. 39, no. 4, 2005, pages 565 - 8, XP001245630, DOI: 10.2144/000112043 DOI: http://dx.doi.org/10.2144/000112043 | PAEZ ET AL.: "EGFR Mutations In Lung Cancer Correlation With Clinical Response To Gefitinib Therapy", SCIENCE, vol. 304, no. 5676, 2004, pages 1497 - 500, XP002359959, DOI: 10.1126/science.1099314 DOI: http://dx.doi.org/10.1126/science.1099314 | TRAXLER ET AL., EXP. OPIN. THER. PATENTS, vol. 8, no. 12, 1998, pages 1599 - 1625 | BARNETT ET AL., BIOCHEM. J., vol. 385, 2005, pages 399 - 408 | JIN ET AL., BR. J. CANCER, vol. 91, 2004, pages 1808 - 12 | SARKARLI, JNUTR, vol. 134, 2004, pages 3493S - 3498S | DASMAHAPATRA ET AL., CLIN. CANCER RES., vol. 10, no. 15, 2004, pages 5242 - 52 | GILLSDENNIS, EXPERT. OPIN. INVESTIG. DRUGS, vol. 13, 2004, pages 787 - 97 | YANG ET AL., CANCER RES., vol. 64, 2004, pages 4394 - 9 | GOLDBERG ET AL., BLOOD, vol. 110, no. 1, 2007, pages 186 - 192 | THOMPSON ET AL., CANCER RES., vol. 13, no. 6, 2007, pages 1757 - 1761 |